Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Frequently asked questions
What sector does Radiopharm Theranostics Limited (RDPTF) operate in?
Radiopharm Theranostics Limited belongs to the Other sector and operates in the Biotechnology industry.
What is Radiopharm Theranostics Limited (RDPTF) current stock price?
As of the latest data, Radiopharm Theranostics Limited stock price is $0.01, with a previous close of $0.01.
What is Radiopharm Theranostics Limited (RDPTF) current market capitalization?
Radiopharm Theranostics Limited market cap is approximately 29.15 million.
What is Radiopharm Theranostics Limited (RDPTF) Earnings Per Share (EPS)?
The trailing EPS is -$0.01.
Does Radiopharm Theranostics Limited (RDPTF) pay dividends?
No. Radiopharm Theranostics Limited does not pay a dividend.
What is Radiopharm Theranostics Limited (RDPTF) beta (volatility) score?
Radiopharm Theranostics Limited has a beta of 0.749, indicating lower volatility than the overall market.
